Lécba chronické proliferativní glomerulonefritidy kyselinou acetylosalicylovou a dipyridamolem
[Treatment of chronic proliferative glomerulonephritis using acetylsalicylic acid and dipyridamole]
Language Czech Country Czech Republic Media print
Document type English Abstract, Journal Article
PubMed
2507156
- MeSH
- Platelet Aggregation drug effects MeSH
- Aspirin administration & dosage therapeutic use MeSH
- Chronic Disease MeSH
- Dipyridamole administration & dosage therapeutic use MeSH
- Adult MeSH
- Epoprostenol biosynthesis MeSH
- Drug Therapy, Combination MeSH
- Humans MeSH
- Glomerulonephritis, Membranoproliferative blood drug therapy metabolism MeSH
- Thromboxane A2 biosynthesis MeSH
- Check Tag
- Adult MeSH
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- English Abstract MeSH
- Journal Article MeSH
- Names of Substances
- Aspirin MeSH
- Dipyridamole MeSH
- Epoprostenol MeSH
- Thromboxane A2 MeSH
Fourteen patients with chronic proliferative glomerulonephritis were given for the period of one year 400 mg acetylsalicylic acid and 225 mg dipyridamole per day. During this treatment the thrombocyte aggregation became normal, however, the mean reduction of antiheparin plasma activity was not statistically significant. Normal synthesis of renal prostacyclin declined significantly as a result of treatment, while the renal thromboxane A2 synthesis remained normal even during treatment. Treatment did not influence proteinuria. The mean annual decline of glomerular filtration was greater during the investigation period than the mean annual decline in previous years, the difference was, however, only at the borderline of statistical significance. The authors did not prove a favourable effect of this treatment in patients with chronic proliferative glomerulonephritis.